FDA warns about seizures among serious health concerns linked with kratom. NIDA also describes seizures in case reports of rare, serious effects. The FDA warning and NIDA research summary support taking these reports seriously. Neither gives a seizure rate or proves what caused one person's event.
Concern about a seizure and concern about substance use can exist together. They do not have to share one reason or one treatment setting. Substance-use treatment in GA should fit the person. Medical needs also matter. A product name alone cannot explain them.
What do FDA and NIDA say about kratom and seizures?
FDA names seizures among serious kratom safety concerns. NIDA describes seizure case reports. A public warning flags reported harm that deserves medical care. In substance-use treatment planning, that concern belongs alongside physical health needs. Neither a warning nor a case report can diagnose a given event.
FDA says it has warned consumers not to use kratom because of serious adverse events. An adverse event is a harmful health event reported in connection with an exposure. The agency lists seizures, liver toxicity, and substance use disorder. These are distinct concerns, not proof that they occur together or have the same cause. FDA's safety statement does not assign a seizure probability.
NIDA places seizures among serious effects described in case reports. It also names confusion and tremors among reported effects involving the brain or nerves. A case report describes what a clinician saw in specific circumstances. Its value is the detail recorded. It cannot represent everyone who uses kratom. NIDA identifies the case-report basis for these findings.
| Evidence type | Useful contribution | Important boundary |
|---|---|---|
| Official warning | FDA identifies seizures as a serious concern. | A warning is not a measured seizure rate. |
| Case report | NIDA describes clinical reports involving seizures. | One observation does not show cause by itself. |
| Experimental research | Lab work explores how kratom compounds act. | A lab finding does not directly measure seizures among users. |
An association means two things occurred together. It does not settle whether one caused the other. A research review brings findings together, while an experiment tests a defined question under set conditions. Neither term should be used as another name for a case report. The kind of evidence matters as much as the headline attached to it.
Can seizure reports prove cause or show how often seizures happen?
No. The seizure reports summarized by NIDA do not show a cause or population rate. Medical care coordination keeps an observed event distinct from a confirmed diagnosis, while addiction treatment planning addresses the person's pattern of use and related needs.
A seizure rate would describe how often seizures occurred within a defined group over time. A collection of reports lacks the complete comparison needed for that calculation. The basic requirements would include:
- A clear count of seizure events in the group.
- A count of people exposed during the same period.
- A defined exposure, group, and time span.
The agency summaries do not provide those seizure-specific data. NIDA uses words such as rare when discussing serious effects in case reports. That wording is not a numerical estimate of seizure incidence, meaning how often new events occur. Dividing a report count by an unrelated national estimate of kratom use would not supply a valid rate. NIDA's summary presents reports and use estimates for different purposes.
Cause is a separate question from frequency. An event happening after kratom use establishes an order in time. Timing alone cannot show which factor produced the event. A report can raise a reasonable concern without settling that question. It should not be treated as proof of either blame or safety.
NIDA says other drugs in the body may affect kratom’s effects. Existing health conditions and past experience can also matter. Those factors may help explain differences between reported events. They do not show the cause of a given seizure. NIDA's discussion of drug interactions and differences among people also stresses the need for more research.
FDA gives a specific caution about deaths associated with kratom. Other drugs were usually involved. Kratom’s role was unclear. That statement concerns deaths. It cannot show that every seizure report involved another drug, or that another drug caused a seizure. Keeping the outcome clear prevents a true statement from becoming a misleading claim. FDA describes that limit explicitly.
How do product differences affect the meaning of seizure reports?
Kratom products differ in form, strength, and contents. A shared name does not mean an identical exposure. NIDA describes wide variation. Care matched to the substance involved still needs room for separate medical concerns, rather than relying on a product label alone.
People use kratom as powder, capsules, tea, or liquid extracts. These forms do not show that products contain the same mix or strength of active compounds. NIDA says both the strength and mix of kratom compounds can change effects. Its product descriptions identify several differences relevant to interpreting an exposure:
- Form: powder, capsules, brewed leaves, or liquid extract.
- Strength: the concentration of active compounds can vary.
- Contents: the mix of kratom compounds can differ.
- Contamination: some products contain harmful substances beyond kratom compounds.
Kratom leaves contain many active chemicals. One is 7-hydroxymitragynine, often shortened to 7-OH. FDA describes it as only a minor natural part of the leaf's total alkaloids, the plant chemicals being studied. A finding about one compound is not automatically a finding about a whole leaf product. FDA distinguishes the plant from its components, and research needs to preserve that difference.
NIDA reports that some users describe energizing effects and others describe effects more like sedation. It also says studies have not shown that these effects depend on the amount or method used. A simple rule about how a product feels therefore cannot serve as a seizure-risk measure. NIDA separates users' reports from established findings.
Contamination is another issue, not a ready reason for seizures. FDA has warned about certain products containing Salmonella or concerning levels of heavy metals. NIDA notes that contaminants can produce effects not due to kratom compounds alone. Neither statement proves what caused a given seizure. The FDA product alerts should not be turned into a seizure estimate for every product.
Do brain studies explain how kratom might cause seizures?
Brain studies explore how kratom compounds work. But they are not the same as proof of a seizure mechanism. NIDA describes that research. Outpatient addiction support is not seizure treatment, and coordination with medical care does not turn an experimental finding into an established treatment.
NIDA says the best-studied kratom compounds include mitragynine and 7-OH. Both act on mu-opioid receptors, small structures on nerve cells that certain drugs activate. Their effects only partly resemble those of other opioids. This gives scientists a starting point for research on the brain. It does not show the cause of a reported seizure. NIDA explains these receptor findings without presenting a proven seizure pathway.
NIDA also describes possible binding of mitragynine at adrenergic, serotonin, and dopamine receptors. These are other sites involved in nerve-cell signaling. The agency says they may help explain arousing effects that some users report. This is another research question about how the compound works, rather than a proven reason for seizures.
Lab work may examine isolated compounds, cells, or animals. NIDA supports such preclinical research, meaning work before or outside treatment studies in people. That work can help shape later questions. It does not replace human evidence about a specific health event. NIDA describes lab research and human research as distinct efforts.
FDA says few published reports come from well-designed studies that gave kratom to humans. It also says results need to be weighed against the many products for sale. A result from a defined study preparation cannot simply stand for every product bearing the kratom name. FDA describes these research limits.
Research into possible benefits is also not approval for treatment. There are no FDA-approved medical uses for kratom, including seizure treatment. People may report using it for pain, cravings, or other concerns, but reported use does not show effectiveness. NIDA distinguishes self-treatment from proven medical use. Neither a proposed benefit nor a lab result cancels the seizure warning.
What care is needed for severe symptoms or immediate danger?
Seek immediate medical care for severe symptoms or immediate danger. NIDA directs people to call 911 or visit an emergency room. Planned medical follow-up and River City Recovery's outpatient services have different roles from emergency care and should not delay it.
NIDA's emergency direction applies to severe symptoms or danger. It does not depend on proving that kratom caused the problem. Its research summary cannot assess a person's current condition. Uncertainty about the cause is not a reason to postpone emergency care when those circumstances are present. NIDA separates emergency help from personal medical advice.
Outside an emergency, NIDA directs people to a qualified health professional for personal medical advice. A clinician can consider the person's circumstances rather than treating an agency summary as a diagnosis for one person. Concern about substance use does not remove that separate need for medical care. NIDA's guidance makes clear that general research information is not a substitute for professional care.
River City Recovery provides adult outpatient addiction care in Columbus, GA. That scope does not include emergency seizure care, onsite medical detox, inpatient care, or residential treatment. An outpatient program should not be assumed to provide a service simply because a health concern involves a substance. Medical care and addiction support can have different responsibilities.
For nonemergency information about River City Recovery's outpatient addiction services, call 706-617-4970 or contact River City Recovery. A discussion about services does not guarantee admission, a specific treatment, or an outcome. Emergency medical needs belong with emergency services, not an outpatient inquiry.
Frequently asked questions
Does FDA warn about seizures linked with kratom?
Yes. FDA lists seizures among serious adverse events associated with kratom and says it has warned consumers not to use kratom. This is an official safety warning. It does not give a seizure rate for all products or prove that kratom caused one person's event. Sources: FDA; NIDA.
Can a case report prove that kratom caused a seizure?
A case report alone cannot prove cause. It describes an observed event in particular circumstances. Other drugs, health conditions, and product differences may matter. Timing can raise concern, but an event happening after kratom use does not by itself establish why it happened. Sources: FDA; NIDA.
How common are seizures among people who use kratom?
The FDA and NIDA summaries do not provide a seizure-specific rate. NIDA describes seizures among rare, serious effects in case reports. That wording is not a numerical estimate. A rate needs a defined group, a time period, and reliable counts of both events and exposure. Sources: FDA; NIDA.
Do laboratory findings establish kratom as a seizure treatment?
No. Laboratory findings about kratom compounds do not show an effective seizure treatment. Research on cells, animals, or brain receptors answers different questions from treatment studies in people. Kratom has no FDA-approved medical use, including seizure treatment. Reported self-treatment is not proof of safety or benefit. Sources: FDA; NIDA.
When should someone seek emergency medical help?
NIDA advises immediate medical attention for severe symptoms or immediate danger, including calling 911 or visiting an emergency department. Do not wait for an outpatient addiction appointment in a medical emergency. The need for emergency help does not depend on first proving that kratom caused the problem. Sources: FDA; NIDA.
By Tim Francis, SUD Content Specialist. Reviewed by clinical staff.
